Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning. Raising its price target on the shares to ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Shares of Hims & Hers Health ( HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...